COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,541 Articles (22,881 medRxiv, 8,660 bioRxiv)

Most recent first Previous |  Page 2429: Articles 24281-24290  | Next

Similarity between mutation spectra in hypermutated genomes of rubella virus and in SARS-CoV-2 genomes accumulated during the COVID-19 pandemic
Gordenin, D. A., Klimczak, L. J., Randall, T. A., Saini, N., Li, J.-L.
10.1101/2020.08.03.234005 — Posted: 2020-08-03 Discussion: Onsite
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Baker, D., Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A., Park, Y.-J., Stewart, L., Diamond, M., Veesler, D.
10.1101/2020.08.03.234914 — Posted: 2020-08-03 Discussion: Onsite
PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Reveals Important Insights into the Outbreak
Maitra, A., Raghav, S., Dalal, A., Ali, F., Paynter, V. M., Paul, D., Biswas, N. K., Ghosh, A., Jani, K., Chinnaswamy, S., Pati, S., Sahu, A., Mitra, D., Bhat, M. K., Mayor, S., Sarin, A., The PAN-INDIA 1000 SARS-CoV-2 RNA Genome Sequencing Consortium, , Shouche, Y. S., Seshasayee, A. S. N., Palakodeti, D., Bashyam, M. D., PARIDA, A., Das, S.
10.1101/2020.08.03.233718 — Posted: 2020-08-03
Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease
Kreutzer, A. G., Krumberger, M., Parrocha, C. M. T., Morris, M. A., Guaglianone, G., Nowick, J. S.
10.1101/2020.08.03.234872 — Posted: 2020-08-03
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., Hou, Y. J., Priya, T., Mitsumoto, M., Pong, A., Lau, U. Y., Mason, M. L., Chen, J., Chen, A., Berrocal, T., Peng, H., Clairmont, N. S., Castellanos, J., Lin, Y.-R., Josephson-Day, A., Baric, R. S., Walkey, C. D., Swanson, R., Blancas-Mejia, L. M., Gale, M., Yen, H.-L., Silva, D.-A.
10.1101/2020.08.03.231340 — Posted: 2020-08-03
Structure of SARS-CoV-2 2'-O-methyltransferase heterodimer with RNA Cap analog and sulfates bound reveals new strategies for structure-based inhibitor design
Rosas-Lemus, M., Minasov, G., Shuvalova, L., Inniss, N., Kiryukhina, O., Brunzelle, J., Satchell, K. J.
10.1101/2020.08.03.234716 — Posted: 2020-08-03
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
Liu, H., Wu, N. C., Yuan, M., Bangaru, S., Torres, J. L., Caniels, T. G., van Schooten, J., Zhu, X., Lee, C.-C. D., Brouwer, P. J. M., van Gils, M. J., Sanders, R. W., Ward, A. B., Wilson, I. A.
10.1101/2020.08.02.233536 — Posted: 2020-08-03
SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98
Addetia, A., Lieberman, N. A. P., Phung, Q., Xie, H., Roychoudhury, P., Loprieno, M. A., Huang, M., Shrestha, L., Jerome, K. R., Greninger, A. L.
10.1101/2020.08.03.234559 — Posted: 2020-08-03
Functional immune mapping with deep-learning enabled phenomics applied to immunomodulatory and COVID-19 drug discovery
Cuccarese, M. F., Earnshaw, B. A., Heiser, K., Fogelson, B., Davis, C. T., McLean, P. F., Gordon, H. B., Skelly, K.-R., Weathersby, F. L., Rodic, V., Quigley, I. K., Pastuzyn, E. D., Mendivil, B. M., Lazar, N. H., Brooks, C. A., Carpenter, J., Jacobson, P., Glazier, S. W., Ford, J., Jensen, J. D., Campbell, N. D., Statnick, M. A., Low, A. S., Thomas, K. R., Carpenter, A. E., Hegde, S. S., Alfa, R. W., Victors, M. L., Haque, I. S., Chong, Y. T., Gibson, C. C.
10.1101/2020.08.02.233064 — Posted: 2020-08-03
SARS-CoV-2 genome sequences from late April in Stockholm, Sweden reveal a novel mutation in the spike protein
Soratto, T. A. T., Darban, H., Bjerkner, A., Coorens, M., Albert, J., Allander, T., Andersson, B.
10.1101/2020.08.03.233866 — Posted: 2020-08-03 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).